Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Bio-Path Holdings, Inc. BPTH

Healthcare  —  Biotechnology
0.00 0.00 NaN as of 25 Sep
Market cap
$1.1M
P/E
0.0×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Bio-Path Holdings, Inc. (BPTH) Business Profile

Updated before January 2025

Company Overview

Bio-Path Holdings, Inc. (BPTH) is a biotechnology company focused on developing innovative therapies for cancer treatment. Founded in 2007, the company is headquartered in Bellaire, Texas, USA. BPTH was established with the mission of revolutionizing cancer treatment through the development of RNAi nanoparticle-based therapeutics. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol BPTH.

The leadership team at Bio-Path Holdings is composed of experienced professionals in the biotechnology and pharmaceutical industries. Peter Nielsen, the CEO and President, has been instrumental in steering the company’s strategic direction and advancing its clinical pipeline. Under his leadership, BPTH has made significant strides in developing its proprietary DNAbilize® platform technology.

Core Business Segments

Bio-Path Holdings operates primarily in the biotechnology sector, with a focus on developing RNAi-based therapeutics for cancer treatment. The company’s core business segments include:

DNAbilize® Platform Technology

BPTH’s proprietary DNAbilize® platform is the cornerstone of its product development efforts. This technology uses neutral lipid-based delivery systems to deliver antisense RNAi molecules directly to cancer cells, effectively silencing specific genes responsible for cancer growth. Key products under this platform include:

  • Prexigebersen (BP1001): A lead candidate targeting leukemia and other hematologic cancers. Prexigebersen is currently in clinical trials and has shown promising results in combination with other therapies.
  • BP1002: A second-generation product targeting solid tumors and hematologic cancers by inhibiting the Bcl-2 protein, which is associated with cancer cell survival.
  • BP1003: A preclinical candidate targeting STAT3, a protein implicated in various cancers, including pancreatic and breast cancers.

Clinical Development Services

In addition to its proprietary products, BPTH offers clinical development services to support the advancement of its therapeutic candidates. These services include preclinical research, clinical trial design, and regulatory support.

Business Model

Bio-Path Holdings operates on a research-driven business model, focusing on the development and commercialization of RNAi-based cancer therapies. The company generates revenue primarily through:

  1. Licensing Agreements: BPTH licenses its DNAbilize® technology to pharmaceutical companies for use in developing their own therapeutic products.
  2. Collaborative Partnerships: The company collaborates with academic institutions and research organizations to advance its clinical pipeline and expand its technological capabilities.
  3. Clinical Trial Funding: BPTH secures funding from government grants and private investors to support its clinical trials and research initiatives.

The company’s approach integrates cutting-edge technology with a patient-centric focus, aiming to address unmet medical needs in oncology.

Strategic Direction

Bio-Path Holdings is committed to advancing its clinical pipeline and expanding its therapeutic portfolio. Key strategic goals include:

  • Pipeline Expansion: BPTH plans to develop additional RNAi-based therapeutics targeting a broader range of cancers, including solid tumors and rare malignancies.
  • Global Market Penetration: The company aims to establish a global presence by seeking regulatory approvals in international markets and forming strategic alliances with global pharmaceutical companies.
  • Sustainability Goals: BPTH is dedicated to minimizing its environmental impact by adopting sustainable practices in its research and manufacturing processes.
  • Innovation in Delivery Systems: The company is investing in the development of next-generation delivery systems to enhance the efficacy and safety of its RNAi therapeutics.

Competitive Landscape

Bio-Path Holdings operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Alnylam Pharmaceuticals: A leader in RNAi therapeutics with a robust pipeline of products targeting various diseases.
  • Ionis Pharmaceuticals: Known for its antisense technology and a strong focus on genetic therapies.
  • Arrowhead Pharmaceuticals: Specializing in RNAi-based therapies for liver and cardiovascular diseases.
  • Moderna Therapeutics: A pioneer in mRNA-based therapeutics with a growing interest in oncology.

Despite the competition, BPTH differentiates itself through its proprietary DNAbilize® platform and focus on hematologic cancers.

Risk Factors

Bio-Path Holdings faces several risks that could impact its business operations and financial performance:

  • Regulatory Challenges: The company’s products must undergo rigorous clinical trials and regulatory approvals, which can be time-consuming and costly.
  • Market Dependence: BPTH relies heavily on the success of its lead candidates, such as Prexigebersen, for revenue generation.
  • Supply Chain Disruptions: The company’s operations could be affected by disruptions in the supply of raw materials or manufacturing delays.
  • Competitive Pressure: Intense competition in the biotechnology sector could limit BPTH’s market share and pricing power.
  • Financial Constraints: As a clinical-stage company, BPTH depends on external funding to support its research and development activities.

Recent Developments

In recent years, Bio-Path Holdings has achieved several milestones:

  • Clinical Trial Progress: The company has advanced Prexigebersen into Phase 2 clinical trials, demonstrating its potential as a combination therapy for leukemia.
  • New Product Development: BPTH has initiated preclinical studies for BP1003, targeting STAT3 in pancreatic and breast cancers.
  • Strategic Partnerships: The company has formed collaborations with leading academic institutions to accelerate its research efforts.
  • COVID-19 Impact: While the pandemic posed challenges to clinical trial enrollment and supply chain operations, BPTH successfully adapted by implementing remote monitoring and virtual trial protocols.

Investment Considerations

Investors considering Bio-Path Holdings should weigh the following factors:

Strengths

  • Innovative Technology: The DNAbilize® platform offers a unique approach to cancer treatment, with the potential to address unmet medical needs.
  • Experienced Leadership: BPTH’s management team has a proven track record in biotechnology and drug development.
  • Strong Pipeline: The company’s clinical pipeline includes promising candidates targeting both hematologic and solid tumors.

Risks

  • Early-Stage Company: As a clinical-stage company, BPTH has yet to generate significant revenue from product sales.
  • Regulatory Uncertainty: The success of BPTH’s products depends on obtaining regulatory approvals, which are not guaranteed.
  • Market Volatility: The biotechnology sector is subject to high levels of market volatility, which could impact BPTH’s stock performance.

Conclusion

Bio-Path Holdings, Inc. is a pioneering biotechnology company with a strong focus on RNAi-based cancer therapeutics. Through its proprietary DNAbilize® platform, the company is developing innovative treatments for hematologic and solid tumors. While BPTH faces challenges such as regulatory hurdles and market competition, its strong pipeline and experienced leadership position it for future growth. As the company advances its clinical trials and expands its global presence, it has the potential to make a significant impact in the field of oncology.